BWA vs RNA · P/E 41, rev $7.18B vs rev $22.6M
BorgWarner Inc (BWA) versus Atrium Therapeutics, Inc. Common Stock (RNA) — a side-by-side from cached financials, not a winner call.
BorgWarner Inc (BWA) is a auto parts company listed on NYSE.
Atrium Therapeutics, Inc. Common Stock (RNA) is a biotechnology company listed on NASDAQ.
Latest reported BWA revenue for 2026-06-30 was $7.18B. Net income was $519.0M. BWA currently screens at market cap $14.47B and trailing P/E 41.0.
Latest reported RNA revenue for 2026-06-30 was $22.6M. Net income was -$36.8M. Revenue was up 15.3% from 2026-03-31 to 2026-06-30. RNA currently screens at market cap $217.5M.
BWA currently screens at market cap $14.47B and trailing P/E 41.0. RNA currently screens at market cap $217.5M.
Not investment advice. Open the BWA and RNA stock pages for the full models.
Not investment advice.